The combination of Cadonilimab (a bispecific antibody targeting PD-1 and CTLA-4) and Anlotinib (a multi-target tyrosine kinase inhibitor) demonstrated a clinically manageable safety profile in patients with extensive-stage small cell lung cancer (SCLC) and brain metastases (BMs). The gene discussed is PDCD1; the disease is small cell lung carcinoma.